Shots:

• The BLA approval is based on the trial assessing Esperoct (turoctocog alfa pegol- N8-GP) in 270 patients with previously treated people (PTPs) with severe haemophilia A
• The study resulted in maintanince of low median ABR of 1.18- efficacious in treatment & control of bleeding episodes- perioperative management and was well tolerated with no safety concerns observed
• Esperoct (turoctocog alfa pegol- N8-GP) is an extended half-life factor VIII molecule indicated as a replacement therapy in people with haemophilia A and will be marketed in US in 2020

| Ref: Novo Nordisk | Image: Azernews